PE20180039A1 - Piroglutamato de vortioxetina - Google Patents
Piroglutamato de vortioxetinaInfo
- Publication number
- PE20180039A1 PE20180039A1 PE2017002418A PE2017002418A PE20180039A1 PE 20180039 A1 PE20180039 A1 PE 20180039A1 PE 2017002418 A PE2017002418 A PE 2017002418A PE 2017002418 A PE2017002418 A PE 2017002418A PE 20180039 A1 PE20180039 A1 PE 20180039A1
- Authority
- PE
- Peru
- Prior art keywords
- vortioxetine
- pyroglutamate
- vortioxetine pyroglutamate
- salt
- forms
- Prior art date
Links
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 title abstract 3
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002263 vortioxetine Drugs 0.000 title abstract 3
- 229940043131 pyroglutamate Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion proporciona la sal de piroglutamato de vortioxetina y composiciones farmaceuticas que comprenden dicha sal. Tambien esta referida a las formas L, D y DL del piroglutamato de vortioxetina en sus formas cristalinas. Una forma preferida de las composiciones es un gel para administracion oral
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500284 | 2015-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180039A1 true PE20180039A1 (es) | 2018-01-09 |
Family
ID=55963369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002418A PE20180039A1 (es) | 2015-05-13 | 2016-05-11 | Piroglutamato de vortioxetina |
Country Status (43)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| WO2018150344A1 (en) | 2017-02-17 | 2018-08-23 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
| EP3532457B1 (en) * | 2017-07-31 | 2020-03-18 | Small Pharma Ltd | Crystalline forms of hydroxynorketamine |
| GB201715950D0 (en) | 2017-10-02 | 2017-11-15 | Croda Int Plc | Gel composition comprising a phase change material |
| KR20220163997A (ko) | 2020-04-03 | 2022-12-12 | 하. 룬드벡 아크티에셀스카브 | 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1006728A (en) * | 1962-12-31 | 1965-10-06 | Mundipharma Ag | Amine salts of pyrrolidone carboxylic acid |
| JPS6160620A (ja) | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US4780667A (en) | 1985-06-25 | 1988-10-25 | Hewlett-Packard Company | Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration |
| FR2694194B1 (fr) | 1992-07-31 | 1994-11-04 | Health Business Dev | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
| CA2262595C (en) | 1996-08-15 | 2005-10-18 | Losan Pharma Gmbh | Easy to swallow oral medicament composition |
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| US8383154B2 (en) | 2004-05-11 | 2013-02-26 | Egalet A/S | Swellable dosage form comprising gellan gum |
| ES2379200T5 (es) * | 2006-06-16 | 2021-10-20 | H Lundbeck As | Bromhidrato de 1-[2-(2,4-Dimetilfenilsulfanil)fenil]piperazina como compuesto con recaptación de serotonina combinada con actividad 5-HT3 y 5-HT1A para el tratamiento del deterioro cognitivo |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| PL2421534T3 (pl) | 2009-04-24 | 2014-12-31 | H Lundbeck As | Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny |
| PT2470166E (pt) * | 2009-08-24 | 2013-10-02 | Lundbeck & Co As H | Novas composições de 1-[2-(2,4-dimetil-fenilsulfanil)- fenil]piperazina |
| EA030433B1 (ru) * | 2010-04-30 | 2018-08-31 | Такеда Фармасьютикал Компани Лимитед | Энтеросолюбильная таблетка |
| CA2885266C (en) * | 2012-09-19 | 2020-05-12 | Sandoz Ag | Novel crystalline form of vortioxetine hydrobromide |
| SG11201506651SA (en) | 2013-02-22 | 2015-09-29 | Lundbeck & Co As H | Vortioxetine manufacturing process |
-
2016
- 2016-05-10 JO JOP/2016/0091A patent/JO3456B1/ar active
- 2016-05-11 HU HUE16721817A patent/HUE042893T2/hu unknown
- 2016-05-11 UA UAA201711057A patent/UA120779C2/uk unknown
- 2016-05-11 AR ARP160101356A patent/AR104591A1/es unknown
- 2016-05-11 PT PT16721817T patent/PT3294719T/pt unknown
- 2016-05-11 SI SI201630176T patent/SI3294719T1/sl unknown
- 2016-05-11 TW TW105114554A patent/TWI700276B/zh not_active IP Right Cessation
- 2016-05-11 PL PL16721817T patent/PL3294719T3/pl unknown
- 2016-05-11 TN TNP/2017/000453A patent/TN2017000453A1/en unknown
- 2016-05-11 ME MEP-2019-11A patent/ME03312B/me unknown
- 2016-05-11 MX MX2017014390A patent/MX2017014390A/es active IP Right Grant
- 2016-05-11 WO PCT/EP2016/060540 patent/WO2016180870A1/en active Application Filing
- 2016-05-11 ES ES16721817T patent/ES2709362T3/es active Active
- 2016-05-11 CA CA2984615A patent/CA2984615C/en active Active
- 2016-05-11 IL IL255466A patent/IL255466B/en unknown
- 2016-05-11 MY MYPI2017001636A patent/MY184965A/en unknown
- 2016-05-11 GE GEAP201614622A patent/GEP20197020B/en unknown
- 2016-05-11 MA MA043397A patent/MA43397A/fr unknown
- 2016-05-11 JP JP2017558957A patent/JP6731001B2/ja active Active
- 2016-05-11 RS RS20190108A patent/RS58263B1/sr unknown
- 2016-05-11 AU AU2016259762A patent/AU2016259762B2/en active Active
- 2016-05-11 BR BR112017024039A patent/BR112017024039B8/pt active IP Right Grant
- 2016-05-11 DK DK16721817.1T patent/DK3294719T3/en active
- 2016-05-11 EP EP16721817.1A patent/EP3294719B1/en active Active
- 2016-05-11 PE PE2017002418A patent/PE20180039A1/es unknown
- 2016-05-11 TR TR2019/01228T patent/TR201901228T4/tr unknown
- 2016-05-11 KR KR1020177032520A patent/KR102551429B1/ko active IP Right Grant
- 2016-05-11 CN CN201680025327.1A patent/CN107567440B/zh active Active
- 2016-05-11 LT LTEP16721817.1T patent/LT3294719T/lt unknown
- 2016-05-11 EA EA201792262A patent/EA032363B1/ru not_active IP Right Cessation
- 2016-05-11 CR CR20170506A patent/CR20170506A/es unknown
- 2016-05-11 RU RU2017139002A patent/RU2713889C2/ru active
- 2016-05-12 US US15/152,902 patent/US10287261B2/en active Active
-
2017
- 2017-10-27 ZA ZA2017/07337A patent/ZA201707337B/en unknown
- 2017-11-02 CO CONC2017/0011295A patent/CO2017011295A2/es unknown
- 2017-11-03 SV SV2017005560A patent/SV2017005560A/es unknown
- 2017-11-03 DO DO2017000260A patent/DOP2017000260A/es unknown
- 2017-11-07 PH PH12017502028A patent/PH12017502028A1/en unknown
- 2017-11-09 CL CL2017002844A patent/CL2017002844A1/es unknown
- 2017-11-10 EC ECIEPI201774919A patent/ECSP17074919A/es unknown
-
2018
- 2018-09-05 HK HK18111409.2A patent/HK1252099B/zh unknown
-
2019
- 2019-01-16 HR HRP20190089TT patent/HRP20190089T1/hr unknown
- 2019-01-24 CY CY20191100089T patent/CY1121171T1/el unknown
- 2019-03-06 US US16/294,647 patent/US11279682B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180039A1 (es) | Piroglutamato de vortioxetina | |
| CL2018001705A1 (es) | Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. | |
| CO2018008207A2 (es) | Composiciones para el cuidado bucal y métodos para utilizar las composiciones | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| GT201600185A (es) | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| BR112018005750A2 (pt) | composições para higiene bucal. | |
| SV2018005643A (es) | Composiciones de insulina de rapida accion | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| BR112017012626A2 (pt) | instrumento para higiene bucal | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| BR112017010947A2 (pt) | instrumento para higiene bucal | |
| BR112017012625A2 (pt) | instrumento para higiene bucal | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| DOP2016000039A (es) | Inhibidores de rorc2 y sus usos | |
| BR112017017199A2 (pt) | instrumento para higiene bucal | |
| BR112018011318A2 (pt) | composições e métodos para higiene bucal | |
| DK3709978T3 (da) | Farmaceutisk oral formulering omfattende bakterier | |
| BR112016020260A2 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| BR112018071370A2 (pt) | composições farmacêuticas orais de mesalazina | |
| BR112017013730A2 (pt) | produto para higiene bucal e métodos para utilização e fabricação do mesmo. | |
| CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
| BR112017022439A2 (pt) | composições para higiene bucal. | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| BR112017010942A2 (pt) | instrumento para higiene bucal |